A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
← catalyst calendarNCT07291232 · readout ≤ 224 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
80estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-19 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: ABBV-295
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to approximately 194 days
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
measured Up to approximately 194 days
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
measured Up to approximately 194 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
measured Up to approximately 194 days
Maximum Observed Plasma Concentration (Cmax) of ABBV-295
measured Up to approximately 194 days
Time to Cmax (Tmax) of ABBV-295
measured Up to approximately 194 days
Trough plasma concentration (Ctrough) of ABBV-295
measured Up to approximately 194 days
Apparent terminal phase elimination rate constant (BETA) of ABBV-295
measured Up to approximately 194 days
Terminal phase elimination half-life (t1/2) of ABBV-295
measured Up to approximately 194 days
Area under the plasma concentration-time curve (AUC) of ABBV-295
measured Up to approximately 194 days
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295
measured Up to approximately 194 days
Dose Normalized Cmax of ABBV-295
measured Up to approximately 194 days
Dose Normalized AUC of ABBV-295
measured Up to approximately 194 days
Incidence of Anti-Drug Antibodies (ADAs)
measured Up to approximately 194 days
Percent Change in Body Weight From Baseline
measured Up to approximately 194 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed